Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-08-19
Item 5.02
The filing discloses the appointment of two independent directors—Wei-Chieh Hao (appointed August 16, 2026) and Richard T. Betts (appointed August 18, 2026)—to the Board, with Hao also appointed as Chairperson of the Corporate Governance and Nominating Committee and Compensation Committee, and Betts as Chairperson of the Audit Committee. While the section also reports two director departures (Wong and Cheng), the principal disclosed actions center on the new appointments and their committee leadership roles, which are material governance changes for a SPAC. The departures are noted as non-contentious and are secondary to the appointment narrative.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-19
The 6-K discloses the appointment of multiple new directors and officers effective August 19, 2026, including the appointment of Li Xiang and Liu Zhenyu as Independent Directors, and the continuation of Huang Hongwu as CEO/Chairman and Wang Xuefei as CFO. While two directors (Wang Zhiyong and Zhang Peng) also resigned, the principal disclosed action is the appointment of new board members and the restructuring of executive leadership, which is material to investors' assessment of governance and management continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-19
Item 5.02
Shun-Chih Chuang was appointed as Chief Financial Officer effective August 17, 2026, under a new Employment Agreement providing annual salary of $84,000 and 100,000 shares annually.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-19
Item 7.01
The filing announces the appointment of Tony Fabrizio as Director, Aerospace and Defense of VisionWave Holdings UK Ltd, a wholly-owned subsidiary. Although the position is at the subsidiary level rather than the parent company, Fabrizio is described as leading business development and sales activities across the United Kingdom and Europe as part of the Company's strategic expansion into international defense and aerospace markets. His 25+ years of defense sector experience and direct role in executing the Company's geographic expansion strategy make this a material executive appointment warranting disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-19
Item 5.02
Granite Ridge appointed two independent directors, John Cocke and Jonathan Adams, to the Board effective August 19, 2026, expanding the Board from seven to nine members and enabling the company to transition from a controlled company to a majority-independent board structure under NYSE listing standards. The appointments include equity compensation and indemnity agreements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Dr. Raj Talluri was appointed as President and Chief Executive Officer effective September 1, 2026, and elected to the Board of Directors effective August 17, 2026. The appointment includes compensatory arrangements with a base salary of $750,000, target bonus of 110%, and equity awards totaling $20 million, replacing an interim CEO with a permanent leader bringing significant prior experience from Enovix, Micron Technology, Qualcomm, and Texas Instruments.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Sam Mehta was appointed President and Chief Executive Officer of L3Harris Technologies effective immediately on August 17, 2026, and was also appointed to the Board of Directors. Mehta brings 25+ years of aerospace and defense experience and previously led the company's largest segments (SMS and CSD) representing 80% of revenue.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The filing discloses the election and appointment of two independent directors, Nicholas J. Ritter and Charles W. Sulerzyski, to Horizon Bancorp's Board of Directors effective August 17, 2026, increasing the board size from 11 to 13 members. Both individuals bring substantial banking and cybersecurity expertise and were assigned to key board committees (Enterprise Risk Management, Operations and Cyber Security, and Wealth Committees). This is a clear executive appointment event under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Vista Gold appointed Gavin Ferguson as Managing Director of Vista Gold Australia Pty Ltd., effective September 7, 2026. Ferguson brings 35+ years of international mining experience, most recently as General Manager of Nevada Gold Mines' Carlin Mining Complex, and will lead the company's flagship Mt Todd gold project development.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matthew Sobczyk was promoted from Corporate Controller to Interim Chief Financial Officer effective August 14, 2026, succeeding Rashed Dewan who resigned from the CFO position. The appointment addresses the company's financial leadership continuity following the departure of the prior CFO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-08-17
Item 5.02
Matt White was appointed as Chief Financial Officer of Bakkt, Inc., effective August 17, 2026, succeeding Karen Alexander. The appointment includes material compensation terms: base salary of $300,000, 90,000 restricted stock units, 60,000 stock options at a $10.00 exercise price, and severance provisions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
The disclosure centers on the appointment of David Sandberg to the Board of Directors effective immediately (Item 5.02(d)), with detailed background on his qualifications and investment holdings. While T. Allan McArtor's resignation is also disclosed (Item 5.02(b)), the substantive focus and length of the filing emphasizes the new director appointment. The appointment is material as it involves a change in board composition and a director with significant beneficial ownership stakes through Red Oak Partners' funds.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-17
Item 5.02
The disclosure centers on Nir Naor's appointment as principal financial and accounting officer on August 12, 2026, and his concurrent appointment as Corporate Secretary, with his title modified to Executive Vice President, Chief Financial Officer, Corporate Secretary, and Treasurer. While the section also mentions Francis X. Brown III's interim role ending, the principal action disclosed is Naor's appointment to key financial and governance roles. The appointment of a CFO and principal financial officer is material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
The disclosure centers on Nadin Virani's appointment as interim Chief Financial Officer effective August 17, 2026, a material executive role. While Edmund Reese's transition from CFO is also disclosed, the principal action emphasized is Virani's appointment to fill the CFO position, supported by details of his background, compensation adjustment ($50,000/month increase), and bonus eligibility. This is a material change in senior leadership affecting investor assessment of the company's financial management.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Maze Therapeutics appointed two new directors to its Board: Paula A. Johnson, M.D., M.P.H. as a Class III director and Sophie Kornowski, Pharm.D. as a Class I director, both effective August 13, 2026. Both appointees bring substantial clinical and biopharmaceutical leadership experience, including prior roles at major pharmaceutical companies and academic institutions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-17
Item 5.02
Fred Stephan was appointed Chief Executive Officer and President effective November 1, 2026, following a deliberate Board succession process. The appointment includes his election as a Class III director and a comprehensive compensation package ($1.15M base salary, $1.44M short-term incentive target, $4.43M long-term incentive target, plus $3.77M and $2M RSU grants). Keith Harvey transitioned from CEO to Executive Chairman as part of this leadership succession.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-17
Item 5.02
CVS Health appointed Teresa Heitsenrether to its board of directors effective November 18, 2026. Heitsenrether is a senior executive from JPMorgan Chase with nearly forty years of financial services leadership experience, bringing expertise in data, analytics, and technology transformation to the company's board during a strategic transition period.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-17
Item 5.02
NNN REIT appointed Christina Chiu and Charles D. Mueller, Jr. to the Board of Directors effective October 1, 2026, as part of staged succession planning. Both appointees bring substantial REIT and executive leadership experience and will serve on the Audit Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 7.01
The filing discloses the appointment of Andra Frazier as Executive Vice President and Chief Credit Officer of CalPrivate Bank, announced via press release on August 17, 2026. This is a named executive appointment to a material C-suite position responsible for credit risk management at a $2.71 billion asset bank. The appointment of a Chief Credit Officer is material to investors assessing the registrant's risk management and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Steven Przybyla was appointed as President of Ispire Technology Inc., effective August 11, 2026, in addition to his existing roles as Chief Legal Officer and Secretary. The appointment strengthens the company's U.S.-based leadership and investor communications capabilities.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-17
The 6-K discloses the appointment of Ms. Shanyu Chang as Chief Financial Officer effective August 17, 2026, following the resignation of Mr. Huaguang Huang. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO), which is the forward-looking governance event. The filing includes biographical information establishing Ms. Chang's qualifications and confirming no conflicts of interest, consistent with exec_appointment disclosure practice.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The Board elected Ret. Lt. Gen. Sean Gainey to serve on the Board and its Nominating and Corporate Governance Committee on August 13, 2026. This is a clear appointment of a director to the Board, which is a material governance event affecting the composition of the registrant's leadership. The disclosure includes his background, compensation arrangements, and standard indemnification agreement, all consistent with a director appointment disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-17
Item 5.02
Constantine Petropoulos was appointed Senior Vice President and Chief Financial Officer effective August 12, 2026. While the disclosure also includes a compensatory arrangement (salary increase from $357,000 to $425,000 and a stock option grant of 25,000 shares), the principal disclosed action is the appointment of an executive to a material C-suite role (CFO). The appointment of a CFO is a significant governance event affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
Jonathan Gutoski was appointed Chief Financial Officer of Edible Garden AG effective August 17, 2026, replacing Kostas Dafoulas who resigned as Interim CFO on August 14, 2026. While the section discloses both a departure and an appointment, the principal disclosed action centers on the appointment of a named executive officer to a key financial leadership role. The disclosure includes Gutoski's background, compensation ($220,000 base salary plus $10,000 signing bonus and up to 25% discretionary bonus), and confirms no related-party arrangements or conflicts of interest.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 65%
filed 2026-08-17
Item 1.01
The Company entered into a Non-Employee Director Agreement with Ximing Huang, formalizing his three-year term as Chairman and CEO. The agreement establishes his executive role and governance position within the Company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
The filing discloses the appointment of Oscar Suarez as an independent director and Audit Committee Chair, effective August 17, 2026. The Board increased from five to six members to accommodate this appointment. Suarez brings over four decades of accounting, tax, and governance experience from Arthur Andersen, KPMG, and EY, making this a material governance event affecting the composition and oversight structure of the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
The filing discloses the appointment of Carol L. Brosgart, MD to Cocrystal Pharma's Board of Directors, effective August 12, 2026. The press release emphasizes her extensive experience in antiviral drug development, FDA approvals, and prior roles at major pharmaceutical companies (Gilead, Tobira), making this a material governance event affecting board composition and strategic direction at a clinical-stage biotech company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-17
EX-99.1
The exhibit announces the appointment of Caroline Levy, a veteran Wall Street consumer analyst with 30+ years of experience and current board member of Celsius Holdings, to Prenetics' Board of Directors as an independent director, with concurrent service on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. This is a material governance event affecting board composition and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The Board of Directors appointed Sarah Watterson as a Class III independent director effective August 17, 2026, expanding the Board from nine to ten members. The appointment includes compensatory arrangements consisting of an annual cash retainer of $75,000 and an RSU grant of $215,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-17
The 6-K discloses the appointment of Andrea Lupo Lanzara as a Class III director of Scorpio Tankers Inc., effective August 17, 2026, to fill a vacancy created by the resignation of Marianne Økland. While both a departure and an appointment occur, the principal disclosed action is the appointment of a new director to the board, making exec_appointment the appropriate classification. Board-level director appointments are material to investors' assessment of governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-17
Item 5.02
The filing discloses the appointment of Kevan P. Krysler as an independent Class I director effective August 13, 2026, with assignment to the Audit Committee. The prose centers on the principal action of a person taking a governance role, supported by his extensive background as CFO of publicly traded Everpure (NYSE: P) and VMware, plus 18 years at KPMG as a partner. This is a material governance event affecting board composition and audit oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-14
Item 5.02
The disclosure centers on the election of Pamela J. Tomczik to the Board of Directors on August 11, 2026, with detailed background on her qualifications and prior roles at Target Corporation, Thomson Reuters, and other companies. While the section also mentions Peter C. Wallace's retirement, the principal action disclosed is Tomczik's appointment as a director, making this an exec_appointment event. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
Robert J. Maines was appointed as Executive Vice President – Chief Operations Officer, effective August 17, 2026, with a salary increase to $440,000 and an equity-based incentive target of $225,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 7.01
Nader Pasdar was appointed as Executive Vice President – Chief Business Officer of Farmer Mac, effective August 17, 2026, bringing 25+ years of experience in agricultural finance and capital markets, including prior service as CEO of Rabo Securities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
Nchacha Etta was appointed Executive Vice President and Chief Financial Officer of U.S. Physical Therapy, effective September 1, 2026. The appointment includes a comprehensive employment agreement specifying a two-year term, $625,000 annual base salary, equity grants totaling approximately $750,000, severance benefits of two years' base compensation upon termination without cause, and change-of-control benefits of $283,333.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
Cable One's Board appointed Heather McCallion as Chief Operating Officer, effective August 24, 2026. McCallion brings 25+ years of executive leadership experience and will be responsible for operational strategy, sales, customer experience, and digital transformation across all regions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
Joshua Pinto, Ph.D., was appointed Chief Executive Officer effective August 14, 2026, and also appointed as a Class III director, succeeding Paul L. Berns who transitioned to Executive Chairperson.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-14
Item 5.02
The filing discloses both the departure of Raymond Barrios as Co-CEO and director (effective August 10, 2026) and the appointment of Eric Hall as Co-CEO and director/Chairman (effective August 11, 2026). While both events occur, the principal disclosed action centers on the appointment of a new Co-CEO and Chairman, making exec_appointment the most salient classification. The appointment of a Co-CEO and Chairman to lead the company is material to investors' assessment of the registrant's governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-14
Item 5.02
The filing discloses both the resignation of Raymond Barrios as President (effective August 10, 2026) and the appointment of Eric Hall as President (effective August 11, 2026). While both events are disclosed, the principal action emphasized is the appointment of Eric Hall to the President role, with his background and existing CEO position detailed. The appointment of a new President is material to investors assessing leadership continuity and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-14
Item 5.02
The filing discloses the appointment of Robert W. Gunning as principal accounting officer effective August 10, 2026, succeeding Louise Kooij. While the disclosure also mentions Kooij's departure, the principal action disclosed is Gunning's appointment to the role, supported by detailed biographical information, compensation terms (base salary $375,000, 30% bonus target, RSU and option grants), and offer letter terms. This is a material executive appointment at a pharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-14
Item 5.08
Byrna Technologies appointed retired U.S. Army Brigadier General Rose Lopez Keravuori to its Board of Directors effective August 10, 2026, and assigned her to a newly formed Enterprise Risk Management Committee. Concurrently, director Emily Rooney resigned, and the company dissolved its Product Safety Committee as part of a board governance restructuring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
The filing discloses the appointment of Wellington J. Reiter as an independent director to fill a newly created fifth board seat, effective August 11, 2026, along with his appointment to the Audit Committee. While compensatory arrangements (RSU grants totaling 210,045 units) are also disclosed, the principal action is the director appointment itself. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
Jason F. Simone was appointed Chief Financial Officer effective August 10, 2026. The disclosure centers on the appointment of an officer to a named executive position, with background on his tenure and prior roles at the company. No compensatory arrangements are being entered into in connection with the appointment, and no departure of a prior CFO is mentioned, making this a straightforward executive appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-14
Item 5.02
The filing discloses the appointment of Seth Cohen to the Board of Directors effective August 12, 2026, with the Board increasing from four to five directors. While the disclosure also mentions Cohen's standard director compensation and indemnification agreement, the principal action is his appointment to the Board and Compensation Committee. This is a material governance event for a newly public company (S-1 effective July 15, 2026) adding a director with significant federal nuclear policy expertise.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-08-14
The 6-K discloses the appointment of Ms. Zhiqin Lu as an Independent Director effective August 14, 2026, following the resignation of Mr. Ow Kian Jing Dennis. While both a departure and appointment occur, the principal disclosed action is the appointment of a replacement director to the Board and Audit Committee. The appointment of an independent director to a public company's board is material to investors' assessment of governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-13
Item 5.02
The Board appointed Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. Ms. Oliger brings 30+ years of biopharmaceutical commercial and operating experience, including senior roles at Genentech leading multi-billion-dollar product portfolios, which is material to the company's advancement toward commercialization.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-13
EX-99.1
Michael Smith, the Company's Chairman, has been appointed as interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow who transitions to a non-executive director role. This is a material executive appointment affecting the Company's top leadership structure and operational control during the interim period while the Company seeks permanent candidates for these critical roles.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-13
Item 5.02
Jill Windrum was appointed as Chief Accounting Officer and Deputy Chief Financial Officer effective August 31, 2026, replacing Brian LaRose as principal accounting officer. This is a material executive appointment to a senior financial leadership role. While the disclosure also includes compensatory arrangements (base salary of $400,000, target bonus of 50%, and sign-on equity awards of $400,000), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-08-13
EX-99.1
The announcement discloses the appointment of Mr. Ying Kang as Assistant Vice President of Finance effective August 13, 2026, with assumption of full oversight of the Finance Department starting August 21, 2026, reporting directly to the CEO. While the exhibit also mentions Dan Xie's departure from the CFO role, the principal disclosed action is Ying Kang's appointment to a senior finance leadership position. This is material as it represents a change in the registrant's financial leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-13
Item 5.02
Jason O'Byrne was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer of Olema Pharmaceuticals, effective August 11, 2026, approved by the Board on July 28, 2026. The appointment includes compensatory arrangements including a base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant. The CEO emphasized O'Byrne's extensive finance and capital markets leadership experience at major biotechnology firms will be essential as the company approaches pivotal clinical data and commercial launch.
View raw filing on EDGAR →